Longmen Capital

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise. The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs.

Innovo Therapeutics is a anti-cancer drug developer committed to research and creation of medications that target protein breakdown.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and drug discovery. Founded in 2010, the company focuses on the development of ion channel-related drugs, particularly targeting the nervous and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel screening, cardiac safety panels, and molecular biology, utilizing proprietary cell lines for voltage-gated and ligand-gated ion channels. The company is also dedicated to expanding its capabilities in immunology, oncology, and other areas, providing comprehensive support for target validation and preclinical candidate identification. Through its advanced screening platforms and flexible collaboration models, ICE Bioscience aims to enhance the efficiency of the drug discovery process for various clinical needs.

Kaidi Medical is a developer of tumor immunotherapy drugs.

Crystal Egg is a biopharmaceutical company dedicated to the independent research and development of first in class innovative new drugs for major diseases such as depression, chronic kidney disease, pain and rare diseases, as well as providing customers with high-quality products and R&D services in membrane protein-related fields. enterprise. The company has built membrane protein expression and purification platforms, structural biology platforms, pharmacology platforms and nanobody screening platforms, and has rich R&D pipelines in the fields of ion channels and GPCRs.

QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.

Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Lyvgen Biopharma Co. Ltd. is a biotechnology company based in Shanghai, China, focused on the research, development, and production of immuno-oncology drug candidates. Established in 2016, the company specializes in a cross-linking-dependent antibody platform that includes proprietary co-stimulation agonist biotherapeutics, such as the PD-1 antibody SSI-361. These products are designed to activate specific receptors within the tumor microenvironment while minimizing immune-mediated adverse effects on healthy tissues. In addition to its therapeutic offerings, Lyvgen Biopharma provides tumor immune agonistic antibodies and services in synthetic biology engineering, aimed at enhancing localized activation of the tumor microenvironment.

Ractigen Therapeutics is an early-stage pharmaceutical company dedicated to developing first-in-class therapies that selectively restore the expression of therapeutic genes silenced in diseased cells. Founded in 2016 by pioneers in the RNA activation field, the company leverages a groundbreaking discovery from the University of California San Francisco, known as RNA activation (RNAa). Ractigen's innovative approach aims to address diseases stemming from inadequate gene expression, with a focus on central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. The company is building a promising pipeline of candidate medicines to meet significant unmet medical needs.

Deyi Sunshine Biotechnology (Beijing) Co., Ltd., founded in April 2013 and located in Zhongguancun Biomedical Park, Beijing, is a biotechnology company dedicated to the research and development of innovative biopharmaceuticals. The company has established a cutting-edge research platform, the Sunshine Protein Optimization Platform, which facilitates the creation of novel therapeutics aimed at treating rare and life-threatening diseases. Its portfolio includes several orphan drugs, such as Pegelan for chronic norovirus infections, Sporphene for articular cartilage injuries, Perox for chronic gout, and Defenfen for lupus erythematosus. Deyi Sunshine holds independent intellectual property rights for the active ingredients of its drug candidates, reflecting its commitment to innovation. The company aspires to address the needs of patients with rare diseases while also looking to expand its therapeutic offerings in the future. Deyi Sunshine is driven by a mission to benefit humanity and improve public health through independent innovation and dedication to excellence in biopharmaceutical development.

Sichuan Huanlong New Material Co., Ltd. is a company dedicated to the development and application of innovative bamboo fiber refining technology. With over 20 years of experience in the bamboo industry, it focuses on expanding the range of bamboo materials and enhancing their value. The company is committed to promoting environmentally friendly products by utilizing bamboo fibers in the manufacturing of various consumer goods, such as tissue paper, paper towels, and toilet paper. By emphasizing sustainable practices, Sichuan Huanlong aims to lead the green ecological bamboo fiber material industry and ensure that bamboo materials are fully recycled and valued.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.

KYEE is a manufacturer of products and services for the medical cloud business that covers many fields, such as medical cloud, smart ward, and big data in health care. The company's process of deepening medical information technology. KYEE helps medical institutions improve service quality and efficiency, ensuring medical safety effectively.

CF PharmTech, Inc. is an independent specialty pharmaceutical company founded in 2007 and headquartered in Suzhou, China. The company specializes in the development and manufacturing of inhalation products, including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. CF PharmTech focuses on creating high-quality and affordable medications for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. In addition to its product development efforts, the company provides contract manufacturing organization (CMO) services, enhancing its capabilities in the global market. With a commitment to effective patient care, CF PharmTech aims to improve management of respiratory conditions through its innovative offerings.

LeapMed is a manufacturer specializing in the production of ultrasound biopsy kits and related consumable items for various medical applications. Their product range includes disposable ultrasonic intervention devices such as precisely positioned puncture racks, biopsy needles, puncture needles, and nerve block needles. The company's focus on research and development aims to enhance medical precision and improve surgical efficiency through innovative ultrasound probes and puncture frames.

SmartNuclide is a company focused on the discovery, manufacture, and marketing of nuclear medicine pharmaceuticals for diagnostic and therapeutic use. It specializes in developing innovative biopharmaceuticals aimed at molecular oncology, targeting both diagnostics and therapeutic formulations. The company has established various research and development pathways for radiopharmaceutical medications, including recombinant proteins and imaging agents. SmartNuclide is committed to providing reliable and effective products to enhance cancer treatment, thereby serving the biotechnology industry with its advanced solutions in nuclear medicine.

SiBionics is a medtech company headquartered in Shenzhen, China, focused on the research, development, and commercialization of active implantable medical devices and medical artificial intelligence. The company specializes in innovative solutions for medical imaging and neuromodulation, striving to create cost-effective products that enhance long-term health monitoring and disease management. SiBionics is developing various advanced technologies, including implanted retinal electrical stimulators, continuous glucose monitoring systems, and screening tools for gastric cancer and chronic diseases. Through the integration of visual coding, artificial intelligence, and medical big data, SiBionics aims to address critical health issues such as retinitis pigmentosa, diabetes, cardiovascular and cerebrovascular diseases, and gastrointestinal tumors, ultimately improving diagnostic and treatment options for these conditions.